Jayne Gurtler

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

Andrew X. Zhu, Richard S. Finn, Mary F. Mulcahy et al. · Clinical Cancer Research · 2013 · 164 citations · Full text

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park et al. · Annals of Oncology · 2015 · 131 citations · Full text

Randomized Multicenter Phase II Trial of Bolus Plus Infusional Fluorouracil/Leucovorin Compared With Fluorouracil/Leucovorin Plus Oxaliplatin As Third-Line Treatment of Patients With Advanced Colorectal Cancer

Nancy E. Kemeny, Carlos A. Garay, Jayne Gurtler et al. · Journal of Clinical Oncology · 2004 · 73 citations · Full text

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Andrew H. Ko, Hagop Youssoufian, Jayne Gurtler et al. · Investigational New Drugs · 2011 · 60 citations

First-line Therapy, Pancreatic Cancer, Phase Ii +8

CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy

William Trent Massengale, Elizabeth I. McBurney, Jayne Gurtler · Journal of the American Academy of Dermatology · 2002 · 32 citations

Lymphoid Neoplasia, Cd20-negative Relapse, Medicine +7